Nawar Dakhallah

Nawar Dakhallah

Auto-generated profile, based on publicly available information

Nawar Dakhallah

Division of Haematology/Oncology, Department of Paediatrics, CHU Sainte-Justine , Montreal, Québec

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
NDNawar Dakhallah
Nawar Dakhallah
APAngela Punnett
Angela Punnett
AYAdam P. Yan
Adam P. Yan

30 January 2026 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
NDNawar Dakhallah
Nawar Dakhallah
JSJonas Steglich
Jonas Steglich
CGClaire Gowdy
Claire Gowdy
SMSarah A Milgrom
Sarah A Milgrom
AAAdina Alazrkai
Adina Alazrkai
SVStephan D Voss
Stephan D Voss
Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.